Správy od Ipsen

What a start to 2026! We announced excellent financial results today.

For Rajminder, the past five years have been marked by challenges that affected every aspect of her life. As a mother and a wife, she struggled to fully participate in the moments that mattered most, while navigating a condition that proved difficult to treat.

The human cost of a system out of balance.

Every scientific breakthrough begins with a question: can this medicine extend life, restore balance, or meaningfully change what is possible for patients? At Ipsen, we are bringing that same discipline to artificial intelligence, asking whether it can help our teams analyse data in new ways,…

Anne Petit does not wait for instructions. She knows that in pharmaceutical development, her team often moves first. “We always need to anticipate the next development phases of a clinical program,” she says. “We need to manufacture the product. It takes time.”

Understanding how partnerships with patient organizations are evolving.

“My job is to be a guardian of patient safety.”

Renal cell carcinoma (RCC) has seen remarkable scientific progress over the past decade. Advances in immunotherapy, targeted agents, and combination strategies have reshaped the treatment landscape and transformed outcomes for many patients. Yet for people living with the most common form of kidney…

Progressive Familial Intrahepatic Cholestasis (PFIC) can be a complex condition. Finding trusted information about PFIC shouldn’t be. PFIC Colors is designed to help families make sense of these conditions and find the information and support they need, fast.

Acute myeloid leukaemia (AML) remains a difficult blood cancer to treat. Despite progress, relapse is still common and long-term disease control remains out of reach for many, especially older patients or those who cannot receive intensive chemotherapy. As we learn more about AML, we are seeing…